Start Your Search
Epidemiology and outcomes (ID 57)
- Event: ELCC 2018
- Type: Poster Discussion session
- Presentations: 1
200PD - High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center (ID 602)
14:45 - 15:45 | Presenting Author(s): C. Fahim
Multidisciplinary cancer conferences (MCCs) aim to improve the management of patients with cancer. We evaluated the rate and type of decision change that occurred at a thoracic MCC.
The MCC took place from June-December 2017 at a Canadian tertiary cancer center and involved surgeons, oncologists, pathologists and radiologists. Cases were brought forward by treating physicians. Using a standardized MCC intake form, physicians articulated a clinical question, original treatment plan, and confidence in the original plan (rated on a 1–5 scale). Major changes were classified as: change from upfront surgery to neoadjuvant treatment, definitive chemotherapy/radiation, or Stereotactic Body Radiation Treatment/Radiofrequency Ablation (SBRT/RFA); change from neoadjuvant or definitive chemotherapy/radiation or SBRT/RFA to surgery; or palliation/observation instead of definitive treatment. Minor changes included additional imaging, further staging investigations, repeat consultations, or changes in planned oncologic or surgical approach. Data were reported as frequencies. Chi-square tests were used to compare groups at a p < 0.05 significance level.
A total of n = 116 cases were reviewed at the MCC. Ninety-six percent of cases required a re-review of imaging or pathology (111/116). Sixty percent (70/116) of cases resulted in a treatment change, with 41% (29/70) and 59% (41/70) of changes considered major and minor, respectively. High physician confidence in the original plan did not significantly correlate with the rate of change (53% no change; 47% change, p = 0.073) or type of change (30% major; 70% minor, p = 0.098). The most common major change was use of neoadjuvant or definitive chemotherapy/radiation instead of upfront surgery (38%, 11/29). Minor changes primarily involved further staging investigations (56%, 23/41).
Sixty percent of cases discussed at the thoracic MCC resulted in a treatment change, with 41% considered major changes. High physician confidence did not significantly correlate with the rate or type of change. These data support the continued implementation and use of MCCs.
Clinical trial identification:
Legal entity responsible for the study:
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.